Major advances have been made in understanding the dynamics of humoral immunity
briefly after the acute coronavirus disease 2019 (COVID-19). However, knowledge …

Background Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone
for public health control of the pandemic and vaccine development. However, current …

The dynamics, duration, and nature of immunity produced during SARS-CoV-2 infection are
still unclear. Here, we longitudinally measured virus-neutralising antibody, specific …

Background COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The
urgent needs for exploring the neutralizing antibodies from patients with different clinical …

Neutralizing antibodies are a major correlate of protection for many viruses including the
novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce …

We investigated the kinetics of severe acute respiratory syndrome coronavirus 2 neutralizing
antibodies in 7 asymptomatic persons and 11 patients with pneumonia. The geometric mean …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic with millions infected and more than 1 million fatalities. Questions regarding the …

The prediction of SARS-CoV-2 immunity by commercially available serologic tests will be
crucial to assess the efficacy of vaccination. We used plaque reduction neutralization testing …

Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …

Background The prevalence and persistence of antibodies following a peak SARS-CoV-2
infection provides insights into its spread in the community, the likelihood of reinfection and …